356 related articles for article (PubMed ID: 32125712)
1. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancerĀ (CRiSP): An international systematic review and meta-analysis.
Tchelebi LT; Lehrer EJ; Trifiletti DM; Sharma NK; Gusani NJ; Crane CH; Zaorsky NG
Cancer; 2020 May; 126(10):2120-2131. PubMed ID: 32125712
[TBL] [Abstract][Full Text] [Related]
2. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J
Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer.
Wu G; Baine MJ; Zhao N; Li S; Li X; Lin C
BMC Cancer; 2019 Oct; 19(1):977. PubMed ID: 31640607
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
[TBL] [Abstract][Full Text] [Related]
5. Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials.
Lehrer EJ; Kishan AU; Yu JB; Trifiletti DM; Showalter TN; Ellis R; Zaorsky NG
Radiother Oncol; 2020 Jul; 148():235-242. PubMed ID: 32505965
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
Shen ZT; Zhou H; Li AM; Ji XQ; Jiang CC; Yuan X; Li B; Zhu XX; Huang GC
J Cancer Res Clin Oncol; 2020 Feb; 146(2):417-428. PubMed ID: 31667573
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
Schellenberg D; Goodman KA; Lee F; Chang S; Kuo T; Ford JM; Fisher GA; Quon A; Desser TS; Norton J; Greco R; Yang GP; Koong AC
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):678-86. PubMed ID: 18395362
[TBL] [Abstract][Full Text] [Related]
8. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
Rajagopalan MS; Heron DE; Wegner RE; Zeh HJ; Bahary N; Krasinskas AM; Lembersky B; Brand R; Moser AJ; Quinn AE; Burton SA
Radiat Oncol; 2013 Oct; 8():254. PubMed ID: 24175982
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Park JJ; Hajj C; Reyngold M; Shi W; Zhang Z; Cuaron JJ; Crane CH; O'Reilly EM; Lowery MA; Yu KH; Goodman KA; Wu AJ
Acta Oncol; 2017 Dec; 56(12):1746-1753. PubMed ID: 28661823
[TBL] [Abstract][Full Text] [Related]
10. Dose Escalation in Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Meta-Analysis.
Zaorsky NG; Lehrer EJ; Handorf E; Meyer JE
Am J Clin Oncol; 2019 Jan; 42(1):46-55. PubMed ID: 29965809
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer.
Ma SJ; Prezzano KM; Hermann GM; Singh AK
Radiat Oncol; 2018 Nov; 13(1):214. PubMed ID: 30400962
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma.
Jiang W; Haque W; Verma V; Butler EB; Teh BS
Acta Oncol; 2019 Sep; 58(9):1259-1266. PubMed ID: 31237185
[No Abstract] [Full Text] [Related]
13. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.
Gurka MK; Collins SP; Slack R; Tse G; Charabaty A; Ley L; Berzcel L; Lei S; Suy S; Haddad N; Jha R; Johnson CD; Jackson P; Marshall JL; Pishvaian MJ
Radiat Oncol; 2013 Mar; 8():44. PubMed ID: 23452509
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
Wild AT; Herman JM; Dholakia AS; Moningi S; Lu Y; Rosati LM; Hacker-Prietz A; Assadi RK; Saeed AM; Pawlik TM; Jaffee EM; Laheru DA; Tran PT; Weiss MJ; Wolfgang CL; Ford E; Grossman SA; Ye X; Ellsworth SG
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):571-9. PubMed ID: 26867885
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1).
Arcelli A; Buwenge M; Macchia G; Bertini F; Guido A; Deodato F; Cilla S; Scotti V; Rosetto ME; Djan I; Parisi S; Mattiucci GC; Cellini F; Fiore M; Bonomo P; Belgioia L; Niespolo RM; Gabriele P; Di Marco M; Simoni N; Mazzarotto R; Morganti AG;
Cancer Med; 2020 Nov; 9(21):7879-7887. PubMed ID: 32910549
[TBL] [Abstract][Full Text] [Related]
16. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.
Dholakia AS; Chaudhry M; Leal JP; Chang DT; Raman SP; Hacker-Prietz A; Su Z; Pai J; Oteiza KE; Griffith ME; Wahl RL; Tryggestad E; Pawlik T; Laheru DA; Wolfgang CL; Koong AC; Herman JM
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):539-46. PubMed ID: 24751410
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Cancer.
Barrord M; Ahmad S; Patel S; Olowokure O; Sussman J; Smith M; Poreddy S; Esslinger H; Latif T; Choe K; Kharofa J
Pancreas; 2020 Aug; 49(7):941-946. PubMed ID: 32658077
[TBL] [Abstract][Full Text] [Related]
18. Whole Pelvic Radiotherapy With Stereotactic Body Radiotherapy Boost vs. Conventionally Fractionated Radiotherapy for Patients With High or Very High-Risk Prostate Cancer.
Wang SC; Ting WC; Chang YC; Yang CC; Lin LC; Ho HW; Chu SS; Lin YW
Front Oncol; 2020; 10():814. PubMed ID: 32547949
[No Abstract] [Full Text] [Related]
19. Propensity-Weighted Survival Analysis of SBRT vs. Conventional Radiotherapy in Unfavorable Intermediate-Risk Prostate Cancer.
Andruska N; Fischer-Valuck BW; Agabalogun T; Carmona R; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Baumann BC
Clin Genitourin Cancer; 2022 Apr; 20(2):123-131. PubMed ID: 35086762
[TBL] [Abstract][Full Text] [Related]
20. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration.
Polistina F; Costantin G; Casamassima F; Francescon P; Guglielmi R; Panizzoni G; Febbraro A; Ambrosino G
Ann Surg Oncol; 2010 Aug; 17(8):2092-101. PubMed ID: 20224860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]